Technology | March 01, 2013

Civco Releases NonInvasive Stereotactic Radiosurgery Solution for Head, Brain Tumors

Civco Medical Solutions trUpoint ARCH Stereotactic Radiosurgery Solution

March 1, 2013 — CIVCO Medical Solutions announced the release of trUpoint ARCH, a new stereotactic radiosurgery (SRS) and stereotactic fractionated radiation (SRT) solution for head and brain tumors.

Stereotactic radiosurgery involves delivering very high doses of radiation quickly, using precisely shaped beams that focus on the tumor and minimize exposure of surrounding healthy tissues and organs. trUpoint ARCH is a frameless solution designed to effectively stabilize a patient’s head in a non-invasive, comfortable hold for delivering the high radiation doses.

“trUpoint ARCH is a solution that produces repeatable results for radiosurgery patients requiring absolute positioning. Our focus when developing new patient positioning and immobilization products is patient comfort and ease of set-up for the clinician; this solution delivers both,” said Nat Geissel, senior vice president and general manager of CIVCO’s radiation oncology business unit.

The trUpoint ARCH system provides clinicians a simple and manageable patient set-up assuring accuracy and repeatability during SRS and SRT treatments. Indexing is available on the device, nasion and the arch design allows flexibility in treatment planning around the device. Compatible with CIVCO’s Universal Couchtop, Posifix thermoplastic system, AccuForm cushions and Protura Robotic Patient Positioning System, trUpoint ARCH provides a comprehensive motion management solution for effective SRS/SRT treatment.

The first cancer center to benefit from this innovative solution is the University Hospital Zurich, Switzerland. They began using trUpoint ARCH with their radiosurgery program in late January 2013.

For more information: www.CIVCO.com

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Overlay Init